Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etrasimod - Pfizer

Next Previous
Drug Profile

Etrasimod - Pfizer

Alternative Names: APD-334; Etrasimod arginine - Pfizer; PF-07915503; VELSIPITY

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Everest Medicines; Pfizer
  • Class 3-ring heterocyclic compounds; Acetic acids; Amino acids; Anti-inflammatories; Benzene derivatives; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Indoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ulcerative colitis
  • Phase II/III Atopic dermatitis; Crohn's disease
  • Phase II Eosinophilic oesophagitis
  • Discontinued Alopecia areata; Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma gangrenosum

Most Recent Events

  • 12 Oct 2024 Updated efficacy and adverse event data from a phase II VOYAGE trial in Eosinophilic oesophagitis presented at the 32nd United European Gastroenterology Week (UEGW-2024)
  • 28 Aug 2024 Everest Medicines plans to launch Etrasimod (VELSIPITY®) in Hong Kong, in the second half of 2024
  • 28 Aug 2024 Everest Medicines plans to launch Etrasimod (VELSIPITY®) in Macau, in the second half of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top